Researchers Generate Better Data with BASi’s Redesigned Raturn™
May 21 2019 - 8:53AM
Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the
“Company”) is pleased to announce the launch of the Company’s
redesigned Raturn™, a movement response system that is designed for
tether-based applications in awake animals.
Used as an alternative to liquid swivels or commutators, the
Raturn™ interactively responds to animal movement to keep
wires, tubing, fluid lines, optic and electrical cables from
twisting. BASi’s Raturn™ systems are used in academic
research, pharmaceutical laboratories, and CROs for a wide range of
applications, including in vivo microdialysis, blood collection,
optogenetics, ECG studies, blood pressure, and activity monitoring.
Since the original launch in the mid-90s, the Raturn™ has
helped researchers produce hundreds of publications for a range of
applications.
“The objective of the Raturn™ is to help researchers obtain
better data by simplifying sample collection while minimizing
stress to the animal,” said Lauren Elolf, PhD, BASi’s Products
Business Development Manager. “It’s a great product, but we
knew we could make it even better. The newly released version of
the Raturn™ offers design improvements and user-friendly
configurations. Even more importantly, the new system is more
affordable, so a greater number of researchers can take advantage
of the benefits it has to offer,” concluded Dr. Elolf.
Demonstrating cross-functional use and high-throughput
capabilities, Raturns™ are available as stand-alone systems,
part of the Culex Automated in Vivo Sampling System, or
customizable configurations as single or multiple units. The
Raturn™ is compatible with BASi’s current line of cage options
and integrates with a number of existing products, further
strengthening the Company’s portfolio to generate better data while
enhancing animal welfare—all at a reasonable price.
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract
research services and monitoring instruments to emerging
pharmaceutical companies and the world's leading drug development
companies and medical research organizations. The Company focuses
on developing innovative services supporting its clients’ discovery
and development objectives for improved decision-making and
accelerated goal attainment. BASi’s products focus on increasing
efficiency, improving data, and reducing the cost of taking new
drugs to market. Visit www.BASinc.com for more
information about BASi.
This release may contain forward-looking statements that are
subject to risks and uncertainties including, but not limited to,
risks and uncertainties related to changes in the market and demand
for our products and services, the development, marketing and sales
of products and services, changes in technology, industry and
regulatory standards, and various market and operating risks
detailed in the company's filings with the U.S. Securities and
Exchange Commission.
Company Contact:Jill C. BlumhoffChief Financial
OfficerPhone: 765.497.8381jblumhoff@BASinc.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/034f438e-4b18-4445-b876-4fa2c49aa10b
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Sep 2023 to Sep 2024